Departments of Anaesthesiology and Intensive Care (L.L.H. and T.M.) and Paediatric Orthopaedic Surgery (L.L.H., H.O., M.L., O.P., and I.J.H.), University of Turku and Turku University Hospital, Turku, Finland.
Department of Biostatistics, University of Turku, Turku, Finland.
J Bone Joint Surg Am. 2020 Feb 5;102(3):205-212. doi: 10.2106/JBJS.19.00650.
Pregabalin as part of a multimodal pain-management regimen has been shown to reduce opioid consumption after spinal surgery in adults but it is unclear whether this is also true in adolescents. Pregabalin has been found to have neuroprotective effects and therefore could have a positive impact on pain after spinal deformity surgery. We conducted a randomized, double-blinded, placebo-controlled clinical trial of adolescent patients undergoing spinal fusion to evaluate the short-term effects of pregabalin on postoperative pain and opioid consumption.
Adolescents with adolescent idiopathic scoliosis, Scheuermann kyphosis, or spondylolisthesis who were scheduled for posterior spinal fusion with all-pedicle-screw instrumentation were randomized to receive either pregabalin (2 mg/kg twice daily) or placebo preoperatively and for 5 days after surgery. The patients ranged from 10 to 21 years of age. The primary outcome was total opioid consumption as measured with use of patient-controlled analgesia. Postoperative pain scores and opioid-related adverse effects were evaluated.
Sixty-three of 77 eligible patients were included and analyzed. Cumulative oxycodone consumption per kilogram did not differ between the study groups during the first 48 hours postoperatively, with a median of 1.44 mg/kg (95% confidence interval [CI],1.32 to 1.67 mg/kg) in the pregabalin group and 1.50 mg/kg (95% CI, 1.39 to 1.79 mg/kg) in the placebo group (p = 0.433). A subgroup analysis of 51 patients with adolescent idiopathic scoliosis showed the same result, with a mean of 1.45 mg/kg (95% CI, 1.24 to 1.65 mg/kg) in the pregabalin group and 1.59 mg/kg (95% CI, 1.37 to 1.82 mg/kg) in the placebo group (p = 0.289). Total oxycodone consumption per hour (mg/kg/hr) was not different between the groups over the time points (p = 0.752). The postoperative pain scores did not differ significantly between the groups (p = 0.196).
The use of perioperative pregabalin does not reduce the postoperative opioid consumption or pain scores in adolescents after posterior spinal fusion surgery.
Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
在成年人脊柱手术后,普瑞巴林作为多模式疼痛管理方案的一部分已被证明可以减少阿片类药物的消耗,但在青少年中是否也如此尚不清楚。普瑞巴林已被发现具有神经保护作用,因此可能对脊柱畸形手术后的疼痛产生积极影响。我们对接受脊柱融合术的青少年患者进行了一项随机、双盲、安慰剂对照的临床试验,以评估普瑞巴林对术后疼痛和阿片类药物消耗的短期影响。
计划接受后路脊柱融合术并使用全椎弓根螺钉固定器的青少年特发性脊柱侧凸、Scheuermann 后凸或脊椎滑脱患者,随机分为术前和术后 5 天接受普瑞巴林(2mg/kg 每日 2 次)或安慰剂治疗。患者年龄在 10 至 21 岁之间。主要结局是使用患者自控镇痛评估的总阿片类药物消耗量。评估术后疼痛评分和阿片类药物相关不良反应。
纳入并分析了 77 名符合条件的患者中的 63 名。术后 48 小时内,研究组之间每公斤累积羟考酮消耗量无差异,普瑞巴林组中位数为 1.44mg/kg(95%置信区间[CI],1.32 至 1.67mg/kg),安慰剂组中位数为 1.50mg/kg(95% CI,1.39 至 1.79mg/kg)(p=0.433)。51 名青少年特发性脊柱侧凸患者的亚组分析也得到了相同的结果,普瑞巴林组平均为 1.45mg/kg(95%CI,1.24 至 1.65mg/kg),安慰剂组为 1.59mg/kg(95%CI,1.37 至 1.82mg/kg)(p=0.289)。各时间点两组每小时(mg/kg/hr)的总羟考酮消耗量无差异(p=0.752)。两组术后疼痛评分无显著差异(p=0.196)。
在接受后路脊柱融合术的青少年中,围手术期使用普瑞巴林并不能减少术后阿片类药物的消耗或疼痛评分。
治疗性 I 级。有关证据水平的完整描述,请参阅作者说明。